Cardiac Changes After Effective Dose Carbetocin for Elective Caesarian Section

Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexFemale
Age18+
SponsorJordan Leitch

About this trial

The goal of this project is to examine the cardiac symptoms and physiologic changes after administration of a reduced dose of carbetocin in participants undergoing elective cesarian section.

* Does reduced dose carbetocin (50mcg) have fewer cardiac side effects than usual dose carbetocin (100mcg) when comparing patient reported symptoms, ECG changes and troponin increases? * Is there a relationship between patient reported cardiac symptoms after carbetocin administration and subjective measures of cardiac ischemia (ECG changes and troponin increases? Researchers will compare 50mcg of carbetocin to the control group of 100mcg of carbetocin in patients undergoing elective cesarian section.

Participants will:

* Be given 50mcg or 100mcg of carbetocin during cesarian section * Asked to report cardiac symptoms * Be assessed for ECG changes and blood loss using standard of practice monitoring * Have a troponin I blood test completed after delivery

Eligibility criteria

Qualifiers

Undergoing elective cesarian section

Primary and repeat cesarian section

Disqualifiers

Prior and current cardiovascular co-morbidities including pre-eclampsia

BMI greater than 50

Pre-existing bleeding disorders

Allergy to carbetocin

Trial design

Treatments tested in this trial

  • Carbetocin

Treatment groups

200 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Jordan Leitch

Lead sponsor

Queen's University

Sponsor institution